DSIP (Delta Sleep-Inducing Peptide)

DSIP stands for delta sleep-inducing peptide, a chain of nine amino acids that the Swiss group around Monnier and Schoenenberger recovered in the 1970s from the blood leaving the brains of rabbits that had been put into an electrically induced sleep state. The name comes from delta waves, the slow brain waves that dominate the deepest stage of non-REM sleep. It was given to people by intravenous drip in a small set of sleep-laboratory studies in the 1980s and early 1990s, and those studies disagreed with each other: some found better sleep efficiency and better daytime alertness, others found changes too small to matter clinically. Nearly fifty years after it was found, researchers still cannot say what DSIP does in the body normally, or even whether the material that antibodies detect in human blood and cerebrospinal fluid is DSIP itself (Kovalzon 2006). It has no approval anywhere as a medicine, and in July 2026 a US Food and Drug Administration advisory committee reviewed it under its international name, emideltide, as a candidate for pharmacy compounding.

• Chronic insomnia, the indication almost all of the human sleep-laboratory work was designed around
• Opiate and alcohol withdrawal, where an uncontrolled 1984 hospital series of 107 inpatients reported rapid relief of physical withdrawal signs (Dick 1984)
• Daytime alertness and performance in people whose night sleep is already disturbed (Schneider-Helmert 1987)
• Off-label use before bed in physique and biohacking circles as a sleep-depth and recovery aid, which is not what the trials tested
• Claimed stress-buffering and neuroprotective effects, which rest on rodent and cell work rather than on human data

Think of a sleeping pill as a hand pushing down on a dimmer switch: it forces the lights down whether the room was bright or not. DSIP behaves more like someone adjusting a thermostat that was already miscalibrated. In the human studies it did little for people who were sleeping normally, and produced its clearest changes in people whose sleep was already broken, which is why the older literature calls it a sleep-promoting substance rather than a sedative. The honest caveat is that nobody has established what that thermostat is wired to, and the effect sizes in the controlled trials were small.

1. First hourIn one small intravenous study a slight arousing rather than sedating effect was seen in the first hour after infusion (Schneider-Helmert 1981).
2. Hours 2-8Sleep-promoting effects in that study appeared only from the second hour after injection, with longer sleep duration and fewer interruptions in chronic insomniacs.
3. Night 1In the seven-night controlled trial, night sleep improved measurably from the very first dose (Schneider-Helmert 1987).
4. Nights 2-7Repeated nightly dosing added further improvement in that trial, with daytime alertness and performance rising significantly; two other trials of the same era called changes of this kind clinically insignificant.
5. Beyond 1 weekNo human data past roughly one week of dosing was located, so anything claimed about weeks or months of nightly use is extrapolation rather than evidence.

• Headache, the only recurring complaint in the largest human series; tolerance was otherwise described as good in 107 withdrawal inpatients (Dick 1984)
• A transient arousing or alerting effect in the first hour after intravenous dosing, the opposite of what most people expect from a sleep compound (Schneider-Helmert 1981)
• No classic sedation, daytime hangover or drug-like side effects were recorded in the small sleep-laboratory studies, which is not the same as none existing; those studies enrolled six to sixteen people each
• Injection-site reactions are not characterised anywhere in the human literature, because every human study located used intravenous infusion rather than the subcutaneous injection used off-label today
• The US Food and Drug Administration has stated that compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration, meaning an immune reaction raised against the peptide
• Because total documented human exposure is a few hundred people across a handful of 1980s studies, uncommon adverse effects would not have been detected at all

• You are pregnant, trying to conceive, or breastfeeding; there is no human reproductive safety data, and DSIP-like material occurs naturally in human colostrum and milk, so the consequences of adding injected peptide are unstudied
• You have an undiagnosed sleep disorder such as obstructive sleep apnoea or narcolepsy, where deepening sleep without treating the cause can delay a diagnosis that matters
• You have major depression or another psychiatric illness under treatment; cerebrospinal fluid DSIP levels differ in depressed and schizophrenic patients compared with healthy volunteers, and what injected peptide does in that setting is unknown
• You are in active opiate or alcohol withdrawal outside a medical setting; the withdrawal reports came from supervised inpatients, not from home use
• You are a competitive athlete under the World Anti-Doping Agency code, since a substance with no regulatory approval anywhere falls under the non-approved substances category
• You are under 18, or you are not working with a physician who knows you are taking it and can monitor you

• Assuming the off-label nightly dose matches the trial dose. The human studies used 25 nanomoles per kilogram intravenously, which for a 70 kg adult is roughly 1.5 mg in a single infusion, several times the 100-250 microgram subcutaneous dose used off-label, and by a different route entirely.
• Expecting a sedative. The literature describes DSIP as sleep-promoting rather than sedating, with minimal effect in people who already sleep well, and one study recorded a slight arousing effect in the first hour after dosing.
• Treating the peptide as a substitute for sleep hygiene, light exposure or a sleep apnoea workup. The controlled trials that showed anything were run in people whose insomnia had already been characterised in a sleep laboratory.
• Reconstituting with tap or spring water, or shaking the vial. Use bacteriostatic water, run it slowly down the vial wall, and swirl rather than shake. Keep the lyophilised powder cold and dark, refrigerate after reconstitution, and discard on the timeline your pharmacist gives rather than stretching one vial over months.
• Stacking it with other sedating compounds, alcohol or prescription hypnotics. No interaction data exists, and combining it with several other unapproved peptides at once makes any adverse effect impossible to attribute.